Natural history of surgically treated high-risk prostate cancer

Alberto Briganti; Robert Jeffrey Karnes; Giorgio Gandaglia; Martin Spahn; Paolo Gontero; Lorenzo Tosco; Burkhard Kneitz; Felix K H Chun; Emanuele Zaffuto; Maxine Sun; Markus Graefen; Giansilvio Marchioro; Detlef Frohneberg; Simone Giona; Pierre I Karakiewicz; Hein Van Poppel; Francesco Montorsi; Steven Joniau; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT)

doi:10.1016/j.urolonc.2014.11.018

Natural history of surgically treated high-risk prostate cancer

Standard

Natural history of surgically treated high-risk prostate cancer. / Briganti, Alberto; Karnes, Robert Jeffrey; Gandaglia, Giorgio; Spahn, Martin; Gontero, Paolo; Tosco, Lorenzo; Kneitz, Burkhard; Chun, Felix K H; Zaffuto, Emanuele; Sun, Maxine; Graefen, Markus; Marchioro, Giansilvio; Frohneberg, Detlef; Giona, Simone; Karakiewicz, Pierre I; Van Poppel, Hein; Montorsi, Francesco; Joniau, Steven; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT).

In: UROL ONCOL-SEMIN ORI, Vol. 33, No. 4, 04.2015, p. 163.e7-13.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Briganti, A, Karnes, RJ, Gandaglia, G, Spahn, M, Gontero, P, Tosco, L, Kneitz, B, Chun, FKH, Zaffuto, E, Sun, M, Graefen, M, Marchioro, G, Frohneberg, D, Giona, S, Karakiewicz, PI, Van Poppel, H, Montorsi, F, Joniau, S & European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT) 2015, 'Natural history of surgically treated high-risk prostate cancer', UROL ONCOL-SEMIN ORI, vol. 33, no. 4, pp. 163.e7-13. https://doi.org/10.1016/j.urolonc.2014.11.018

APA

Briganti, A., Karnes, R. J., Gandaglia, G., Spahn, M., Gontero, P., Tosco, L., Kneitz, B., Chun, F. K. H., Zaffuto, E., Sun, M., Graefen, M., Marchioro, G., Frohneberg, D., Giona, S., Karakiewicz, P. I., Van Poppel, H., Montorsi, F., Joniau, S., & European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT) (2015). Natural history of surgically treated high-risk prostate cancer. UROL ONCOL-SEMIN ORI, 33(4), 163.e7-13. https://doi.org/10.1016/j.urolonc.2014.11.018

Vancouver

Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L et al. Natural history of surgically treated high-risk prostate cancer. UROL ONCOL-SEMIN ORI. 2015 Apr;33(4):163.e7-13. https://doi.org/10.1016/j.urolonc.2014.11.018

Bibtex

@article{be8fccd7cfca4b86ba86b1a2955eb077,

title = "Natural history of surgically treated high-risk prostate cancer",

abstract = "BACKGROUND: No data exist on the patterns of biochemical recurrence (BCR) and their effect on survival in patients with high-risk prostate cancer (PCa) treated with surgery. The aim of our investigation was to evaluate the natural history of PCa in patients treated with radical prostatectomy (RP) alone.MATERIALS AND METHODS: Overall, 2,065 patients with high-risk PCa treated with RP at 7 tertiary referral centers between 1991 and 2011 were identified. First, we calculated the probability of experiencing BCR after surgery. Particularly, we relied on conditional survival estimates for BCR after RP. Competing-risks regression analyses were then used to evaluate the effect of time to BCR on the risk of cancer-specific mortality (CSM).RESULTS: Median follow-up was 70 months. Overall, the 5-year BCR-free survival rate was 55.2%. Given the BCR-free survivorship at 1, 2, 3, 4, and 5 years, the BCR-free survival rates improved by+7.6%,+4.1%,+4.8%,+3.2%, and+3.7%, respectively. Overall, the 10-year CSM rate was 14.8%. When patients were stratified according to time to BCR, patients experiencing BCR within 36 months from surgery had higher 10-year CSM rates compared with those experiencing late BCR (19.1% vs. 4.4%; P<0.001). At multivariate analyses, time to BCR represented an independent predictor of CSM (P<0.001).CONCLUSIONS: Increasing time from surgery is associated with a reduction of the risk of subsequent BCR. Additionally, time to BCR represents a predictor of CSM in these patients. These results might help provide clinicians with better follow-up strategies and more aggressive treatments for early BCR.",

keywords = "Aged, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Risk Factors, Journal Article",

author = "Alberto Briganti and Karnes, {Robert Jeffrey} and Giorgio Gandaglia and Martin Spahn and Paolo Gontero and Lorenzo Tosco and Burkhard Kneitz and Chun, {Felix K H} and Emanuele Zaffuto and Maxine Sun and Markus Graefen and Giansilvio Marchioro and Detlef Frohneberg and Simone Giona and Karakiewicz, {Pierre I} and {Van Poppel}, Hein and Francesco Montorsi and Steven Joniau and {European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT)}",

year = "2015",

month = apr,

doi = "10.1016/j.urolonc.2014.11.018",

language = "English",

volume = "33",

pages = "163.e7--13",

journal = "UROL ONCOL-SEMIN ORI",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "4",

}

RIS

TY - JOUR

T1 - Natural history of surgically treated high-risk prostate cancer

AU - Briganti, Alberto

AU - Karnes, Robert Jeffrey

AU - Gandaglia, Giorgio

AU - Spahn, Martin

AU - Gontero, Paolo

AU - Tosco, Lorenzo

AU - Kneitz, Burkhard

AU - Chun, Felix K H

AU - Zaffuto, Emanuele

AU - Sun, Maxine

AU - Graefen, Markus

AU - Marchioro, Giansilvio

AU - Frohneberg, Detlef

AU - Giona, Simone

AU - Karakiewicz, Pierre I

AU - Van Poppel, Hein

AU - Montorsi, Francesco

AU - Joniau, Steven

AU - European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT)

PY - 2015/4

Y1 - 2015/4

N2 - BACKGROUND: No data exist on the patterns of biochemical recurrence (BCR) and their effect on survival in patients with high-risk prostate cancer (PCa) treated with surgery. The aim of our investigation was to evaluate the natural history of PCa in patients treated with radical prostatectomy (RP) alone.MATERIALS AND METHODS: Overall, 2,065 patients with high-risk PCa treated with RP at 7 tertiary referral centers between 1991 and 2011 were identified. First, we calculated the probability of experiencing BCR after surgery. Particularly, we relied on conditional survival estimates for BCR after RP. Competing-risks regression analyses were then used to evaluate the effect of time to BCR on the risk of cancer-specific mortality (CSM).RESULTS: Median follow-up was 70 months. Overall, the 5-year BCR-free survival rate was 55.2%. Given the BCR-free survivorship at 1, 2, 3, 4, and 5 years, the BCR-free survival rates improved by+7.6%,+4.1%,+4.8%,+3.2%, and+3.7%, respectively. Overall, the 10-year CSM rate was 14.8%. When patients were stratified according to time to BCR, patients experiencing BCR within 36 months from surgery had higher 10-year CSM rates compared with those experiencing late BCR (19.1% vs. 4.4%; P<0.001). At multivariate analyses, time to BCR represented an independent predictor of CSM (P<0.001).CONCLUSIONS: Increasing time from surgery is associated with a reduction of the risk of subsequent BCR. Additionally, time to BCR represents a predictor of CSM in these patients. These results might help provide clinicians with better follow-up strategies and more aggressive treatments for early BCR.

AB - BACKGROUND: No data exist on the patterns of biochemical recurrence (BCR) and their effect on survival in patients with high-risk prostate cancer (PCa) treated with surgery. The aim of our investigation was to evaluate the natural history of PCa in patients treated with radical prostatectomy (RP) alone.MATERIALS AND METHODS: Overall, 2,065 patients with high-risk PCa treated with RP at 7 tertiary referral centers between 1991 and 2011 were identified. First, we calculated the probability of experiencing BCR after surgery. Particularly, we relied on conditional survival estimates for BCR after RP. Competing-risks regression analyses were then used to evaluate the effect of time to BCR on the risk of cancer-specific mortality (CSM).RESULTS: Median follow-up was 70 months. Overall, the 5-year BCR-free survival rate was 55.2%. Given the BCR-free survivorship at 1, 2, 3, 4, and 5 years, the BCR-free survival rates improved by+7.6%,+4.1%,+4.8%,+3.2%, and+3.7%, respectively. Overall, the 10-year CSM rate was 14.8%. When patients were stratified according to time to BCR, patients experiencing BCR within 36 months from surgery had higher 10-year CSM rates compared with those experiencing late BCR (19.1% vs. 4.4%; P<0.001). At multivariate analyses, time to BCR represented an independent predictor of CSM (P<0.001).CONCLUSIONS: Increasing time from surgery is associated with a reduction of the risk of subsequent BCR. Additionally, time to BCR represents a predictor of CSM in these patients. These results might help provide clinicians with better follow-up strategies and more aggressive treatments for early BCR.

KW - Aged

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Prognosis

KW - Prostate-Specific Antigen

KW - Prostatectomy

KW - Prostatic Neoplasms

KW - Risk Factors

KW - Journal Article

U2 - 10.1016/j.urolonc.2014.11.018

DO - 10.1016/j.urolonc.2014.11.018

M3 - SCORING: Journal article

C2 - 25665508

VL - 33

SP - 163.e7-13

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 4

ER -